"Azfdin" is not accidental from Henan, the key lies in him ...

At the beginning of the heart, Azfdin's "seed" was born in the laboratory; when scientists encountered entrepreneurs, "seeds" found "soil" to market -oriented; Seeds are fruits.

The original intention of the inventor Chang Junbiao

As the inventor of Azfdin, the former president of Henan Normal University, Chang Junbiao, deputy secretary and vice president of Zhengzhou University Party Committee, set the start time of the research in 2003.

In 2003, the "SARS" raged and became an indelible collective scar in China. In the same year, Chang Junbiao, who had returned from his studies, embarked on the long road of innovative medicine research.

For more than ten years before, Chang Junbiao completed studies from bachelor, master, doctoral, postdoctoral, and American visiting scientists. The goal of creating innovative medicines is becoming more and more firm.

"At that time, Henan was the same as the whole country. There were few antiviral drugs and less innovative drugs. It mainly relied on imported drugs and generic drugs. I think we should have drugs with completely independent intellectual property rights." Stress, very people can imagine. From R & D to listing, it basically takes 10 to 15 years, and its investment from $ 2 billion to US $ 3 billion, which was an astronomical number at the time.

In 2003, Chang Junbiao started the original drug design work. At that time, he did not conquer the ambition of "SARS", let alone predict that there would be "new crowns" in the future. He just definitely should do this. "If you want to do this well, you must like it from the heart. I have been in college from college. This is the case."

Azf must be a general name, and its chemical name is 1- (4-losing nitrogen-2-deoxy-2-fluorine-β-D-Fu nucleotanl) cytopine, which belongs to nucleoside drugs. At the beginning of the study, Chang Junbiao clearly made innovative nucleoside drugs as a research direction. The molecular amount of nucleoside compounds is small, with an average of only about 300. The room for transformation is small. Drugs are important drugs for the treatment of virus infectious diseases and tumors clinically. Therefore, although the molecular weight of nucleoside compounds is small, it supports the development of more than 100 clinical drugs globally. About 60%of the antiviral drugs currently used are nucleoside drugs.

"Among the 10,000 compounds, one pilot compound may be found for research and development, but even so, the final success rate is also very low." Chang Junbiao said that in the subsequent period of time, he led the team to thousands of designed synthesis of thousands of design. Activation screening in individual compounds was finally selected for "excellent varieties".

In 2007, Azf would usher in the first important node. This year, the R & D team led by Chang Junbiao applied for the synthetic nucleoside activated compound for the national invention patent. This is a complete original compound that laid a solid foundation for the listing of Azf in the future.

"Chaoyang Complex" of entrepreneur Chaoyang

Good scientific research results, if they are lying in the laboratory, they cannot truly benefit humans. When a scientist meets an entrepreneur, the fate gear rotates, and Azf will usher in another important time node.

Chaoyang, from Lushan County, Pingdingshan City, has founded a business in multiple fields in the early days and has accumulated a capital foundation. Occasionally, Chang Junbiao met with the Chaoyang, and two people who had forward -looking people in their respective fields reached a consensus. Chaoyang developed well in the traditional field at that time, but he said that his name was Chaoyang and hoped that in the future, he would be able to lay out in a more rising industrial field.

According to the Pingdingshan Daily, Jing Wenzhi, deputy general manager of Henan True Biotechnology Co., Ltd., still remembers a dialogue with him more than ten years ago.

Chaoyang said, "Do the best to do, do those who contribute to humans (things)."

Jing Wenzhi said, "It's big."

Chaoyang said, "Not big, just wait to see it."

The transformation of the Chaoyang is the same frequency as the transformation of his city.

Builded for coal and prosperous because of coal, Pingdingshan City is a typical resource -based city. Entering the 21st century, the "Coal City" Pingdingshan began to actively seek green transformation. In 2011, in 2011, Pingdingshan successively introduced many policies and measures such as accelerating the development of strategic emerging industries to guide the optimization and upgrading of the industrial structure.

In December 2011, Chaoyang reached an Azfdin patent transfer agreement with Zhengzhou University at a price of 40 million, and began to enter the field of innovative drug research and development that rarely touched the country at that time.

The reporter learned that the generation of innovative drugs requires a variety of stages such as preparation of compounds, pre -clinical research, clinical trials, listing registration, and new drug monitoring. Among them, drug clinical trials are divided into phase I clinical trials, phase II clinical trials, phase III clinical trials, phase IV clinical trials, and biological equivalent tests.

After getting Azfdin's patent, Chaoyang registered Henan Real Biotechnology Co., Ltd. (hereinafter referred to as real creatures) in September 2012. The company will be responsible for subsequent clinical trials and registration and assume the cost of registering and registering and registering and registering and registering. Essence

"After the patent transfer, the responsibility and risk of promoting the listing of Azf's new drugs to the real creature, I concentrated on scientific research." Chang Junbiao said.

"At that time, this patent was just a conceptual medicine. It may be possibly padded or pangoic medicine in the future. The return was great uncertainty. It was certain that the large amount of funds and manpower inputs needed in the process of promoting the listing of new drugs were certain. A high -investment and high -risk field. "Real biological leaders said.

Du Jinfa's "Doctoral Group" by chief scientist Du Jinfa

In addition to a large amount of capital investment, innovative drug research and development must rely on talents.

At the end of 2015, Du Jin, who was engaged in the development of new drugs in the United States for more than 20 years, returned to China. Join the real creature and serve as the company's CEO and chief scientist.

In terms of innovative drug research and development, Du Jinfa has a very rich experience -before that, he designed drugs Sofibwe, which treats hepatitis C. The medicine was acquired by Geely for $ 11 billion in 2012; The US FDA approves the listing, and the high cure rate has made it an epoch -making drug in the field of hepatitis C.

Later, with Du Jinfa as the chief scientist, real creatures gathered the management team mainly "doctoral groups" such as the party and Guo Changyue and the scientific advisory team mainly based on the Chinese Academy of Engineering Jiang Jiandong. The establishment of a clinical, registration and commercial team in Beijing has built a production base in Pingdingshan.

In the meantime, Azfdin's phase I clinical research and phase II clinical research continued to advance.

In December 2019, the real creature held a seminar at the Azfdin Phase III Phase III, announcing that the first category 1 type of oral anti -HIV drug Azfding was about to carry out phase III clinical research.

At the same time, a sudden new crown pneumonia epidemic is starting to spread ...

Academician Jiang Jiandong's gratitude

Although the patent is transferred, Chang Junbiao's research on Azfdin has never stopped.

"After receiving the task, we did not have passed the Spring Festival. We immediately joined the laboratory and began an emergency research against the research of new crown pneumonia related drugs." Chang Junbiao said that in early 2020, the new crown pneumonia's epidemic struck. , Henan Province's new coronary virus prevention and control emergency research project "drug screening of anti -new coronary virus" was approved by the Henan Provincial Department of Science and Technology.

Through experiments, the research team quickly locked the target to Azfdin. After research, Azfdin has a suppressive effect on the new coronary pneumonia virus. This is because Azf has the effect of broad -spectrum inhibition of RNA virus replication. Although the new coronal virus is different from HIV virus, it belongs to the RNA virus as a genetic material. Azfdin, as a nucleoside analog of inhibitory RNA -dependent RNA polymerase (RDRP), can specific effects on the new coronary virus RDRP, thereby inhibiting virus replication.

At the beginning of 2020, when the Henan scientific research team was screened against the screening of new coronary virus drugs for emergency research, Jiang Jiandong, an academician of the Chinese Academy of Engineering and the dean of the Chinese Academy of Medicine Research, also led researchers to set up a new crown drug scientific research project team. They screened nearly 500 listing drugs and candidate compounds, and more than 60 drugs were found to have anti -coronary virus activity at the cell level. From these 60 drugs, two "promising coronary drugs" were found, and Azf must be one of them. As the holder of Azfdin's pharmaceutical listing, real creatures have received unprecedented attention and the help of many scientific researchers -for the same goal, many scientific research teams have put in Azf's clinical trials in Azf's clinical trial At work.

"Clinical trials show that Azf will significantly increase the nucleic acid ride yin rate, significantly shorten the time of rotation, and shorten the patient's hospitalization time in patients with new crown pneumonia. Drugs, Azf will also have the advantages of convenient administration, conservative targets, and easy production and storage.

On July 20, 2021, Azf was settled in the first highlights -the National Drug Administration approved the first type of innovative drugs to approve the real biological declaration of Azf fixed -healing HIV adaptation through the preferential review and approval procedure Symptoms.

On July 25, 2022, Azf fixed to a higher scientific peak, picking up the "Pearl on the Crown" in the field of innovative drugs -the National Drug Administration attached to the actual biological Azf fixed tablet Application for the registration of virus pneumonia adaptation, Azf became the first self -administered anti -new crown drug in my country to be approved to be listed, and it was also the first type of innovative drugs to be approved to be listed in Henan.

"Chemical teachers of real biological and Henan Normal University, biomedical researchers at the Institute of Medicine and Biotechnology, Pharmaceuticals, Kunming Institute, and Animal Institute of the Chinese Academy of Medical Sciences, clinical experts from Beijing Union Medical College, Beijing Earth Temple Hospital, Wuhan Central South Hospital, Henan, Henan Provincial hospitals including more than ten hospitals in the provincial hospitals, experts at Peking University Statistics, and engineers at Beijing Union Pharmaceutical Factory ... "On July 28, 2022, the 14th Health China Forum, Jiang Jiandong thanked the new crown pneumonia After the epidemic, the relevant units participated in the research and development of Azf's research and development. He said: "The development of new drugs is extremely difficult, and cooperation and cooperation have played a key role in decisive."

02

Azf Ding and Innovation Henan

"Scientific and technological innovation must be 'top sky', not only the goal of the goal, the courage to climb the peak of science, dare to pick up the‘ pearl on the crown ’, and make scientific research on the Central Plains land, and fully transform the scientific research results in a timely manner.

How much is the 1 -type innovative medicine?

In the dimension of class 1 innovative drugs, Azf must be a "zero breakthrough" in Henan.

In the dimension of autonomous intellectual property oral resitration of new crown drugs, Henan is the "zero breakthrough" in the country.

Talking about the feelings when I learned that Azf's fixed film was approved, Chang Junbiao once choked: "It is not because of seeing hope, but because you can see the hope."

What does 1 type of innovative medicine mean?

According to my country's laws and regulations, drug registration is registered and managed in accordance with Chinese medicine, chemical drugs and biological products.

Chemical drug registration classification is divided into innovative drugs, improved new drugs, generic drugs, and non -listed chemicals in overseas.

Category 1: Innovative medicines that have not been listed at home and abroad. Refers to drugs containing new structures, pharmacological effects, and clinical value;

Class 2: New drugs that have not been listed at home and abroad;

Category 3: Domestic applicants imitation of drugs that have been listed abroad but have not been listed in the country but have not been listed in China;

Category 4: Domestic applicants imitation of drugs that have been listed in the country in China;

Category 5: Applications for drugs listed abroad are listed in the country.

As a type of innovative medicine for chemicals, Azf's fixed tablet means that its originality is not only domestic, but also abroad.

The "2021 Drug Review Report" released by the State Drug Administration shows that in 2021, 1,886 (998 varieties) were applied for the National Innovation Pharmaceutical Registration in 2021, an increase of 76.10%year -on -year; 2412 Application for Clinical Test Test (IND), a year -on -year increase of growth, year -on -year growth 55.81%; 389 applications for listing of new drugs (NDA), an increase of 20.43%year -on -year.

From the final result, there are only 47 innovative drugs passed in 2021, and the data is hit for a record high, and the difficulty and value of innovative drugs to be approved can be imagined.

It is worth noting that this time Azf is designated as an attachment approval, and behind it is the background of the country's encouragement of the development of innovative drugs -starting on December 1, 2019, the newly revised drug management law has begun to implement. The first time after 18 years was fully amended. In order to accelerate the listing of new drugs, a series of system dividends were released, including the qualified approval system. For diseases that have severe life and have no effective treatment methods, and drugs that are urgently needed in public health, clinical trials existing data shows the curative effect, and can be approved by conditions that can predict clinical value. This system has shortened the development of clinical trials for the development of clinical trials Time enables patients who need to be treated with new medicine as soon as possible.

Two years and five months, the cumulative research and development expenditure reached 284 million yuan

Although the "acceleration package" with qualified approval is used, behind the listing of Azfding, the time, funds, manpower, material resources, etc. are still huge.

The person in charge of the real creature describes this difficult years with three "10" -10 years, invested 1 billion yuan, and a success rate of 10%. When the company was the most difficult time, weeds in the courtyard were crowded, and everyone joked that grass was higher than people.

In the process of promoting the listing of innovative drugs, funds are like continuing the blood of life and need to be continuously entered.

Real creatures recently submitted to the Main Board of the Hong Kong Stock Exchange show that in the first May of 2020, 2021 and 2022, other revenue and income of real creatures were 68,000 yuan, 1.376 million yuan, and 8.451 million yuan. During this period Losses were 151 million yuan, 197 million yuan, and 218 million yuan, respectively, with a cumulative loss of 566 million yuan.

For the cause of losses, real creatures said that they are mainly used for R & D investment, capital expenditure and sales expenses. Among them, in the past two years and the first five months of this year, the cumulative research and development expenditure of real creatures reached 284 million yuan.

Where does money come from?

According to reports, in addition to the company's early investment, in November 2020, real creatures completed Series A financing, led exclusively by Yifeng Capital, and financing for innovative drug technology research and development and market expansion.

In August 2021, real creatures completed a round B financing of 100 million US dollars. This round of financing was led by Yifeng Capital and Yingke Capital. The project registration and the commercialization of Azfdin, which have been approved, and so on.

In addition, the government also provides various support for innovation and development.

Among them, in 2020, real creatures received special funds for the development of Talent Development of the "Eagle City British Plan" of Pingdingshan; in the same year, the real creature "Azfding (FNC) treatment of new coronary virus infection pneumonia" project was obtained Support.

According to the official website of the Provincial Department of Science and Technology, in recent years, the Ministry of Science and Technology of China and the Henan Provincial Department of Science and Technology have successively passed the national key research and development plan, Henan's new coronary virus prevention and control emergency research project, and Henan Province's major science and technology special anti -new coronary drug screening hosted by Chang Junbiao It also gives continuous support for R & D, and has invested nearly 30 million yuan in financial funds.

"Everything is prepared, only the General Administration of the General Administration"

The registered place and headquarters of real creatures are located in the urban -rural integration demonstration area of ​​Pingdingshan. The listing of Azf is the "big event" of the local municipal party committee and municipal government.

On May 7, 2019, Zhang Leiming, then mayor of Pingdingshan City (the current Secretary of the Pingdingshan Municipal Party Committee) and the Real Biological New Pharmaceutical R & D team held work talks to accelerate the construction comminicate. According to incomplete statistics, Zhang Leiming has participated in real biological related activities eight times since 2019.

On December 15, 2021, the "Pingdingshan Municipal People's Government and Henan Normal University Strategic Cooperation Framework Agreement" signed, and the mayor of Pingdingshan City Zhao Wenfeng attended the ceremony.

Sun Guoquan, director of the Pingdingshan Market Supervision Bureau, introduced that in the first half of this year, the Pingdingshan Municipal Party Committee and the Municipal Government clearly were led by the Market Supervision Bureau to serve the listing of new drugs for Azf. At that time, the real creatures needed a drug production license. On April 18, the Pingdingshan Market Supervision Bureau submitted the corporate materials to the Provincial Drug Administration; on the morning of April 25, Sun Guoquan ran to Zhengzhou and asked the approval progress. Knowing that it was possible to issue a certificate that morning, Sun Guoquan waited at the site of the Provincial Drug Administration. The permit came out, and he took the person in charge of the enterprise as soon as possible to let him come to get it as soon as possible.

"After April, I basically go to the enterprise every day, and I can't remember how many times I have run." Lu Yanhao, Chief of the Pharmaceutical Department of Pingdingshan Market Supervision Bureau, told Dahe News Dahe Cai Cube reporter. The pharmaceutical production license is down, and the drug GMP certification is required. In the meantime, the epidemic control was encountered. In order to complete the GMP certification as scheduled, the Food and Drug Inspection Institute of Pingdingshan Market Supervision Bureau provided relevant inspection instruments, equipment, and reagents for enterprises, and sent five inspection professionals to support enterprises. In the end, the enterprise pharmaceutical GMP compliance inspection information was reported on May 10th. The expert group completed the on -site inspection work of the enterprise GMP compliance inspection on May 13, and completed the task 2 days in advance.

After Azf's relevant test was passed, Sun Guoquan sighed and sent a WeChat to Zhang Leiming: "Everything is ready, only the General Administration is owed by the General Administration."

It is not accidental

Azf is set to Henan, not accidental.

The Henan Provincial Party Committee's Working Conference held on September 7, 2021 proposed that the "two guarantees" anchor, implement the "top ten strategies", insist on putting innovation on the logical starting point of development, drive innovation drivers, science and education provinces, and strong talents. The provincial strategy is in the "Top Ten Strategy". Since then, innovative Henan has run out of "acceleration".

On July 17, September 23, and October 20, 2021, Henan successively unveiled the three provincial laboratories: Songshan Lab, Shennong Seed Industry Lab, and Yellow River Laboratory.

On December 28, 2021, the unveiling ceremony of the rebuilding and reviving Henan Provincial Academy of Sciences was held in the Central Plains Science and Technology City.

From February 23 to 24, 2022, Lou Yangsheng, secretary of the Provincial Party Committee, went to Pingdingshan City to investigate. In real creatures, Lou Yangsheng checked the production process of biopotics, and learned about the work and living conditions of R & D personnel. Innovation ecology allows scientists to focus on innovation and entrepreneurs at ease. On March 22, 2022, the unveiling ceremony of the second batch of provincial laboratories, provincial and middle -aged trial bases, and Industrial Research Institute was held. Lou Yangsheng, Secretary of the Provincial Party Committee, was unveiled in 3 provincial laboratories, 13 provincial trial bases, and 15 provincial industrial research institutes. In his speech, Lou Yangsheng pointed out that scientific and technological innovation must be "standing in the sky". It must be first -rate, and to climb the peak of science, dare to pick up the "pearl on the crown", and make scientific research on the land of the Central Plains, and to fully translate it in time and fully transform. Scientific research results.

A series of actions in Henan have released a strong signal of unswervingly driving high -quality development of "Huashan Road" to innovate.

On January 6, 2022, at the sixth session of the 13th Provincial National People's Congress, the governor Wang Kai made a government work report, and for the first time, the annual expected goal of the year proposed that "more than 1.96%of the investment in R & D investment" was proposed.

It is understood that in 2021, Henan Province's R & D investment exceeded the 100 billion yuan mark for the first time, the technical contract turnover exceeded 60 billion yuan, and the province's high -tech enterprises in the province increased by 30%year -on -year. Essence

Azf's approved listing is the epitome of innovating Henan. Azf is the first, but not the only one, and more innovative medicines are under development.

Lei Shengyun, secretary of the Party Group of Henan Provincial Pharmaceutical Bureau, said in an interview with Henan Daily that it was a steady -handed detachment overtaking and a lane in the provinces of the provinces of medical demand and the provinces of traditional Chinese medicine. Azf is the first type of innovative drugs with independent intellectual property rights in Henan Province, which has made a good start for the high -quality development of the pharmaceutical industry.

At present, the anti -lung cancer 1 innovative drug "mole sulfininibicinib" developed by Professor Chang Junbiao's team is conducting phase I clinical trials. Phase III clinical trial.

In addition to Azfdin, there are many other new drugs in real creatures. In October 2021, Henan's first batch of provincial industrial research institutes and the China -test bases were unveiled, and Henan Provincial Institute of Modern Pharmaceutical Industry was officially landed. The relevant person in charge of the company told the Dahe News Daily Dahecai Cube reporter that in the field of anti -tumor, the company's independently developed lung cancer therapy drug -Dokibinib is implementing phase Ⅰ and phase II clinical trials; in the field of cardiovascular and cerebrovascular disease treatment; The new type of cerebral infarction therapeutic drugs independently developed by the company are undergoing preclinical research. In addition, in addition to the treatment of new crown pneumonia, real creatures are also studying the possibility of exploring Azfding in the future of more difficult diseases. Azf's treatment of lymphoma, lymphocyte leukemia, and multi -myeloma indication have been completed in clinical research.

More new drug research and development industries are laying on the land of the Central Plains.

Recently, the "Henan Province Promoting the Implementation Plan for Biological Economic Development" was issued, proposing that the added value of the biological economy at the end of the "14th Five -Year Plan" was more than 500 billion yuan, and the value -added of core industries such as biomedicine increased by about 10%. The pharmaceutical foundation and the concentration of scientific research institutes have the advantages of building a highland and industrial cluster of the biological industry; supporting Nanyang to build a national first -class biomedical industry base in the country. Among them, the Zhengzhou Airport Experimental Zone Linkong Biomedical Industrial Park is the largest life science and biomedical research and development and production innovation and entrepreneurial base under construction in Henan Province.

03

Azfdin's future road

From the supply of raw materials to the ultimate tablet, what links do Azf will go through the middle? How can Azf's marketization after the factory is fixed?

The reporter of the Dahe Daily · Dahecai went into the production workshop of Azf's raw material medicine and the solid agent workshop, etc., and felt the production process of the first domestic new crown oral medication at a close range.

Produced in Xinxiang medicine in the new village, which can meet market demand

On July 30, a reporter from the Dahe Daily · Dahe Cai Cube entered the listed company in Xinxiang City Takinxin Pharmaceutical. Tuoxin Pharmaceutical subsidiary Xinxiang Pharmaceutical Co., Ltd. (hereinafter referred to as Xinxiang Pharmaceutical) is a partner of real creatures. It has the production license of Azf's raw medicine, which is mainly for real creatures to supply Azf's raw medicine.

Xinxiang Pharmaceutical's Azf Stand -up Materials Production Line passed the on -site inspection of the Food and Drug Review and Inspection Center in Henan Province in April this year, and officially obtained production qualifications.

According to He Bin, deputy general manager of Xinxiang Pharmaceutical, the Azf St. Materials produced by Xinxiang Pharmaceuticals will play a key role in treating new crown pneumonia as a drug.

In the workshop in Azf's sperm -based dry bag (refined, dry, and packaging process), the reporter of the Dahe News Dahe Cai Cube saw that the workers were busy using polyethylene, aluminum foil and other packaging Azoff. Package, packed and then closed into the dedicated storage bucket, and then enter the finished warehouse. Azf's raw materials need to be stored in a dedicated warehouse below 25 ° C, so that it will not affect the stability of the medicine.

"At present, Xinxiang Pharmaceutical Azf's Symptoms Production Line has all the conditions for mass production and can be continuously produced to meet market demand. In the future, the rhythm of production will be adjusted according to market conditions." He Bin said.

After being put into production in Pingdingshan, the annual production capacity is about 1 billion slices of drugs from Xinxiang Pharmaceutical production, and it must be transported to the tablet production line. At present, the production enterprises of Azf's fixed films include real biological and Peking Union Pharmaceutical Factory.

On the morning of August 2nd, after Azf's fixed film was put into production in Pingdingshan, a reporter from the Dahe News Daily Dahecai entered the solid agent workshop of the real creature and visited the production process of Azfding.

In the solid system workshop, the staff told reporters that Azf's fixed tablets must go through the process of granules, pressures, bottles, outer packaging and other processes in this workshop. A compressor machine can produce 240,000 pieces per hour.

It is understood that Azf, which is constructed by Pingdingshan, has a production plant. The total construction area is about 22,262 square meters, and the annual output capacity is about 1 billion tablets Azfdin. The annual output of the future preparation may reach 3 billion pieces.

Zhang Yi, Secretary of the Party Working Committee of the Urban and Rural Integrated Demonstration Zone of Pingdingshan City, said that in the next step, the urban -rural integrated demonstration zone will focus on supporting real biological speed speed up production and expanding production capacity. Difficulties encountered in the link, comprehensively mobilize the coordination of various functional departments in the area directly, and coordinate the point and one -on -one coordination solution to serve enterprises to speed up the development.

In the front line, the medicine has arrived in Hainan, Xinjiang and other places

In fact, in the process of R & D in Azf, many listed companies have issued an announcement with real biological cooperation, but most of them are framework cooperation agreements and do not have substantial production or sales cooperation.

On July 25, Fosun Pharmaceutical Holding subsidiary Fosun Pharmaceutical Industry and real creatures signed the "Strategic Cooperation Agreement" to reach a strategic cooperation on promoting the joint development of both parties and the exclusive commercialization of Fosun Pharmaceutical Industry Azfding.

According to the cooperation agreement, Fosun Pharmaceutical Industry enjoys the exclusive commercialization of cooperative products, and commercialization includes acting, importing, exporting, sales, and promotion.

Recently, the epidemic in Hainan, Xinjiang and other places struck. On August 11, Fosun Pharmaceutical Industry joined the real biological emergency to prepare Azf's fixed films to help many places across the country. At present, medicines have been arrived one after another.

Fosun Pharmaceutical Industry said in an interview with the reporter of the Dahe Dao Dahecai Cube that the current Azf, who is currently in the emergency support of many places, must be used in the first line of resistance, that is, the designated treatment hospital, which is temporarily not available on the market.

In terms of price, according to the price of medical insurance networks in various places, Azf is priced at 270 yuan per bottle, 35 tablets per bottle, and 1 mg per piece. The amount of usage is swallowed by the entire space, 5mg each time, once a day, the course of treatment is not more than 14 days.

Monthly fundraising, providing financial support for Azfding's follow -up research

On the evening of August 4, the real biological submitted a listing application to the Hong Kong Stock Exchange, which was the exclusive sponsorship.

The real creature said that the raised funds will be used to treat the manufacturing and commercialization of Azfdin's core product of the new crown pneumonia. And the use of other general enterprises.

Real creatures said that with the company's advanced technology platform and powerful R & D capabilities, the company has established a wide and competitive product pipeline, especially in the field of antiviral drugs.

As of now, real creatures have 17 patents and patent applications to be approved in China; 23 patents and patent applications are approved overseas overseas. In addition, real creatures hold 12 trademarks in Mainland China and Hong Kong and 8 applications to be approved in Mainland China.

At the same time, the real creatures in the application also announced the future development strategy: quickly and efficiently promoting the commercialization of Azf's covid-19 and HIV infection and the supervision process after listing; Drugs; continue to expand the research and development platform and expand product pipelines, strengthen production and commercialization capabilities to support future commercialization activities; strengthen talent training through internal training and recruitment.

Make Chinese contribution to the prevention and control of global epidemic

The real creature proposed in the listing application that it is planned to seek to include Azf into the Chinese national medical insurance directory. Recently, this wish has been responded by relevant national departments.

On August 9th, the General Office of the National Health and Health Commission and the General Office of the National Health and Health Commission issued a notice that Azf's fixed tablet was included in the "New Coronary Virus Pneumonia Diagnosis and treatment plan (ninth edition)". In the treatment of adult patients with COVID-19) for the treatment of ordinary new type of coronary virus pneumonia.

On August 12, the National Medical Insurance Bureau stated that in accordance with the relevant provisions of basic medical insurance, in order to better guarantee the needs of diagnosis and treatment, all drugs included in the new coronary pneumonia diagnosis and treatment plan can be temporarily included in the scope of medical insurance payment. After Azf's fixed tablet is included in the new type of coronary virus pneumonia diagnosis and treatment plan, the medical insurance fund can be paid as regulations when using the drug.

"The development of drugs is a long -term process. In the next step, we must continue to study Azf." Chang Junbiao said. According to the relevant provisions of the Drug Management Law, after the drug is listed, it is necessary to continue to carry out the research of drugs, and further confirm the safety, effectiveness and quality control of the drug in order to strengthen the continuous management of the available drugs. "I hope more teams and more platforms in the future can produce and develop more innovative medicines made by Henan!"

"We will effectively fulfill the responsibility of the first responsible person of the drug safety, comprehensively strengthen the quality management of Azf's fixed life cycle, and ensure that the drug production and operation are continuously legal and compliant."Continue to use innovation as a driver, strive for more innovation results, and contribute to the development of Henan and Pingdingshan for the development of the country and the global pharmaceutical industry.Azf's all -industry chain is in Henan, and is contributing to China for the treatment of new crown pneumonia and the prevention and control of the epidemic.

————————————————————————

Source: Dahecai Cube

- END -